Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

Zanubrutinib demonstrated a 5-year progression-free survival (PFS) rate of 72.2% and overall survival rate of 85.1% in patients with deletion of the 17p chromosome (del[17p]) chronic lymphocytic ...

The Voice features host Gloria Burns in a meaningful conversation with Roxie Soto from the Leukemia & Lymphoma Society (LLS) to highlight the organization’s mission, patient support programs, ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed ...

Several clinical trials in leukemia and lymphoma have started enrolling recently. Maybe one of your patients could benefit from taking part? Hematological malignancy scheduled for a human leukocyte ...

Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections. Blood cancers increase ...